Metropolitan Life Insurance Co NY Raises Holdings in Sangamo Therapeutics Inc (NASDAQ:SGMO)

Metropolitan Life Insurance Co NY increased its holdings in Sangamo Therapeutics Inc (NASDAQ:SGMO) by 20.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 38,292 shares of the biopharmaceutical company’s stock after acquiring an additional 6,557 shares during the period. Metropolitan Life Insurance Co NY’s holdings in Sangamo Therapeutics were worth $347,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of SGMO. Steward Partners Investment Advisory LLC purchased a new position in Sangamo Therapeutics in the second quarter worth approximately $50,000. Virginia Retirement Systems ET AL boosted its position in shares of Sangamo Therapeutics by 13.6% during the second quarter. Virginia Retirement Systems ET AL now owns 20,900 shares of the biopharmaceutical company’s stock worth $225,000 after buying an additional 2,500 shares during the period. Creative Planning boosted its position in shares of Sangamo Therapeutics by 91.1% during the second quarter. Creative Planning now owns 55,104 shares of the biopharmaceutical company’s stock worth $593,000 after buying an additional 26,265 shares during the period. SG Americas Securities LLC purchased a new position in shares of Sangamo Therapeutics during the second quarter worth $229,000. Finally, DekaBank Deutsche Girozentrale boosted its position in shares of Sangamo Therapeutics by 168.8% during the second quarter. DekaBank Deutsche Girozentrale now owns 152,400 shares of the biopharmaceutical company’s stock worth $1,608,000 after buying an additional 95,700 shares during the period. Institutional investors own 70.83% of the company’s stock.

Several research firms have recently commented on SGMO. Cowen restated a “buy” rating on shares of Sangamo Therapeutics in a research report on Monday. Zacks Investment Research lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 16th. Wedbush restated a “hold” rating and set a $11.00 price target on shares of Sangamo Therapeutics in a research report on Wednesday. HC Wainwright began coverage on Sangamo Therapeutics in a research report on Monday, August 26th. They set a “buy” rating and a $16.00 price target for the company. Finally, BidaskClub upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, November 28th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Sangamo Therapeutics currently has an average rating of “Buy” and an average target price of $13.50.

SGMO opened at $8.68 on Friday. Sangamo Therapeutics Inc has a 52 week low of $6.26 and a 52 week high of $13.91. The business has a fifty day simple moving average of $9.87 and a 200-day simple moving average of $10.26. The firm has a market cap of $995.93 million, a P/E ratio of -12.40 and a beta of 2.84. The company has a quick ratio of 4.77, a current ratio of 4.77 and a debt-to-equity ratio of 0.10.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.10. The firm had revenue of $21.96 million during the quarter, compared to analyst estimates of $12.16 million. Sangamo Therapeutics had a negative return on equity of 30.33% and a negative net margin of 159.12%. Sangamo Therapeutics’s revenue was down 6.8% compared to the same quarter last year. During the same period last year, the business posted ($0.13) earnings per share. Sell-side analysts expect that Sangamo Therapeutics Inc will post -1.2 earnings per share for the current year.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

Read More: What is the formula for the cash asset ratio?

Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics Inc (NASDAQ:SGMO).

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.